Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of PRX-03140 as Monotherapy in Subjects With Alzheimer's Disease.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2011
Price :
$35
*
At a glance
- Drugs PRX 3140 (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors EPIX Pharmaceuticals
- 31 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Jun 2008 The expected completion date for this trial is Jan 2010 as reported by ClinicalTrials.gov.
- 05 Jun 2008 Status changed from initiated to recruiting as reported by ClinicalTrials.gov